C
3.13
-0.08 (-2.49%)
| 前收盘价格 | 3.21 |
| 收盘价格 | 3.17 |
| 成交量 | 2,417,696 |
| 平均成交量 (3个月) | 2,750,048 |
| 市值 | 627,154,944 |
| 价格/销量 (P/S) | 2.55 |
| 股市价格/股市净资产 (P/B) | 8.51 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2026 |
| 营业毛利率 | -10.23% |
| 营业利益率 (TTM) | -13.54% |
| 稀释每股收益 (EPS TTM) | -0.100 |
| 季度收入增长率 (YOY) | 12.70% |
| 总债务/股东权益 (D/E MRQ) | 176.82% |
| 流动比率 (MRQ) | 2.32 |
| 营业现金流 (OCF TTM) | 8.56 M |
| 杠杆自由现金流 (LFCF TTM) | 7.81 M |
| 资产报酬率 (ROA TTM) | -3.82% |
| 股东权益报酬率 (ROE TTM) | -35.69% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Cerus Corporation | 混合的 | 混合的 |
AIStockmoo 评分
-0.7
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.5 |
| 平均 | -0.67 |
|
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 3.35% |
| 机构持股比例 | 76.13% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合